2.4.0.8150 - Disclosure - Significant Contractual Service and Milestone Agreements - Additional Information (Detail)truefalsefalse1false USDfalsefalse$eol_PE10315---13S-1-0008_STD_31_20120228_0_711809x716723http://www.sec.gov/CIK0001069308duration2012-01-29T00:00:002012-02-28T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE10315---13S-1-0008_STD_366_20121231_0_711809x716723http://www.sec.gov/CIK0001069308duration2012-01-01T00:00:002012-12-31T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse1false USDtruefalse$eol_PE10315---13S-1-0008_STD_31_20120228_0_711809x716723http://www.sec.gov/CIK0001069308duration2012-01-29T00:00:002012-02-28T00:00:00falsefalseService agreement with Pharmaceutical Research Associates Incus-gaap_PartiesToContractualArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ServiceAgreementsMemberus-gaap_PartiesToContractualArrangementAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Service agreement with Pharmaceutical Research Associates Inc2true 3opxa_ScheduleOfContractualCommitmentsLineItemsopxa_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule Of Contractual Commitments [Line Items]3false 4us-gaap_PaymentsForFeesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse543766543766USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid during the current period for fees which are not defined elsewhere in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 false2Upfront cash payment4false 4opxa_ExpectedFuturePaymentsopxa_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3760537605USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryExpected Future PaymentsNo definition available.false2Expected future upfront cash payment5false 4opxa_AgreementInitialTermopxa_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse004 yearsfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaAgreement Initial TermNo definition available.false0Agreement initial term6false 4opxa_AgreementsAdditionalTermAfterRenewalInYearsopxa_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse001 yearfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaAgreements Additional Term After Renewal In YearsNo definition available.false0Agreements additional term after renewal in years7false 4opxa_PriorWrittenNoticePeriodForTerminationOfAgreementopxa_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse0060 daysfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaPrior Written Notice Period For Termination of AgreementNo definition available.false0Notice period before termination of agreement8false 4us-gaap_ProfessionalFeesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse13822361382236USD$falsetruefalsexbrli:monetaryItemTypemonetaryA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849 false2Total payment charged to expensefalseSignificant Contractual Service and Milestone Agreements - Additional Information (Detail) (Service agreement with Pharmaceutical Research Associates Inc, USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.opexatherapeutics.com/taxonomy/role/DisclosureSignificantContractualServiceAndMilestoneAgreementsAdditionalInformation28